683 Capital Management’s SQZ Biotechnologies Company SQZ Stock Holding History

683 Capital Management’s Portfolio SQZ Stock Details SQZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,330,889	Closed	-$985K	–	341
2022 Q4	$985K	Sell	1,330,889 -914,111	-41%	-$2M	0.08%	123
2022 Q3	$5.12M	Buy	2,245,000 +87,262	+4%	+$262K	0.4%	64
2022 Q2	$6.86M	Buy	2,157,738 +58,923	+3%	+$212K	0.48%	64
2022 Q1	$10.1M	Buy	2,098,815 +246,680	+13%	+$1.57M	0.54%	48
2021 Q4	$16.5M	Buy	1,852,135 +159,748	+9%	+$1.96M	0.61%	39
2021 Q3	$24.4M	Buy	1,692,387 +317,216	+23%	+$4.3M	0.95%	27
2021 Q2	$19.9M	Buy	1,375,171 +787,193	+134%	+$10.3M	0.69%	36
2021 Q1	$8.04M	Buy	587,978 +121,802	+26%	+$2.47M	0.43%	58
2020 Q4	$13.5M	Buy	+466,176	New	+$11.9M	0.64%	40

Other funds holding SQZ

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

683 Capital Management's SQZ Position: Q1 2023 in Review

683 Capital Management sold out of SQZ Biotechnologies Company (SQZ) in Q1 2023, closing a stake of 1,330,889 shares — an estimated $985K sold.

683 Capital Management first reported a position in SQZ in Q4 2020 and held it in 9 quarters. The position peaked at $24.4M in Q3 2021. 32 funds tracked by Wall St. Rank hold SQZ as of Q1 2023.

683 Capital Management reported no remaining SQZ Biotechnologies Company position as of Q1 2023 after selling out during the quarter.
683 Capital Management sold 1,330,889 SQZ Biotechnologies Company shares in Q1 2023, an estimated $985K.
683 Capital Management first reported a position in SQZ Biotechnologies Company in Q4 2020 and held it in 9 quarters.
683 Capital Management's SQZ Biotechnologies Company position peaked at $24.4M in Q3 2021.
32 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.